Skip to content

Intravenous Lidocaine and Acute Rehabilitation

Intravenous Lidocaine Infusion Improves Outcome After Laparoscopic Colectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00330941
Enrollment
45
Registered
2006-05-29
Start date
2003-01-31
Completion date
2004-12-31
Last updated
2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Consumption, Postoperative, Pain, Postoperative, Postoperative Fatigue

Brief summary

Background: Intravenous infusion of lidocaine may decrease postoperative pain and speed return of bowel function. The investigators therefore tested the hypothesis that including perioperative lidocaine infusion improves recovery from laparoscopic colectomy and shortens the duration of hospitalization. Methods: Forty patients scheduled for laparoscopic colectomy were randomly allocated to receive intravenous lidocaine (bolus injection of 1.5 mg.kg-1 lidocaine at induction of anesthesia, then a continuous infusion of 2 mg.kg-1.h-1 intraoperatively and 1.33 mg.kg-1.h-1 for 24 h postoperatively) or an equal volume of saline. All patients received similar intensive postoperative rehabilitation. Postoperative pain scores, opioid consumption, and fatigue scores were measured. Times to first flatus, defecation, and hospital discharge were recorded. Postoperative endocrine (cortisol and catecholamines) and metabolic (leucocytes, C-reactive protein, and glucose) responses were measured for 48 h. Data (median \[25%-75% interquartile range\] Saline vs Lidocaine groups) were analyzed using Mann-Whitney tests. P\<0.05 was considered statistically significant.

Interventions

DRUGlidocaine

Sponsors

University of Liege
CollaboratorOTHER
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* ASA I-III * non-malignant disease

Exclusion criteria

* greater than 70 years * history of gastro-duodenal peptic ulcer or renal failure (contraindications to the use of nonsteroidal anti-inflammatory drug) * hepatic insufficiency * psychiatric disorder * steroid treatment * chronic treatment with opioid

Design outcomes

Primary

MeasureTime frame
Sevoflurane consumption
Pain scores
abdominal comfort
fatigue scores

Secondary

MeasureTime frame
hospital stay
endocrine and metabolic responses
bowel function

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026